Document text
Principal Investigator: Yuan Shi
Organization: UNIVERSITY OF CALIFORNIA LOS ANGELES
Fiscal Year: 2020
Award: $390,000
Funding agency: National Institute of Allergy and Infectious Diseases
Project Summary
Influenza A virus causes disease in 5-20% of the population with over 200,000 hospitalizations annually in US.
The antigen drift and shift of influenza virus pose a serious challenge for flu vaccination program. Although IFN
response is known as the first important host defending mechanism to control influenza virus replication at
different steps, influenza virus has acquired many strategies to suppress/antagonize IFN function effectively
allowing its replication in the hosts. It is well known that influenza viral nonstructural protein 1 antagonizes IFN
function through suppressing IFN production. However, less is known on how influenza virus counteracts
function of IFN-stimulated genes (ISGs), many of which have antiviral functions. Our recently developed a
quantitative and high-throughput genomics system has enabled the identification of novel IFN-sensitive
mutations on multiple viral segments across influenza genome. The goal of this project is to determine how
influenza virus antagonizes host anti-viral mechanism by studying recently identified novel IFN-sensitive
mutations using a comprehensive genomic and proteomic platform in vitro and in vivo. The research plan
focuses on three motifs on influenza viral proteins PA, PB1, and M1. Each motif, represented by multiple
mutations located together in a small surface area, might target a cellular protein or step of IFNR signaling
pathway. In addition, our preliminary data suggest mutations on the M1 motif interact with IFN production
pathway, while motifs on PA and PB1 may counteract ISGs downstream of IFN production. The hypothesis is
that these three anti-IFN motifs of influenza PA, PB1, and M1 interact with cellular proteins to antagonize IFN
functions. A series of complementary approaches including high-density mutagenesis, mRNA display-deep
sequencing, ISG cDNA library screening, CRISPR/Cas9 gene editing, human lung primary culture system, and
gene knockout mice are proposed in three independent while logically connected Specific Aims (SAs) to test
our scientific hypothesis. SA#1 is to define the motifs on viral proteins PA, PB1, and M1 that are critical for the
anti-IFN functions. SA#2 is to utilize WT and mutant viral proteins containing IFN-sensitive mutations to
determine the cellular proteins interacting with the anti-IFN motifs. In SA#3 is to determine the functional
interaction and its biological impact in vitro and in vivo. The completion of proposed project will reveal
mechanism for the anti-IFN strategy used by influenza virus, advance our understanding of influenza
pathogenesis, and provide valuable targets for more effective influenza vaccine and anti-viral therapy.
Terms: <Amino Acids><Antigens><Antiviral Agents><Antiviral Drugs><Antiviral Therapy><Antivirals><Area><Attenuated><Binding><Biological><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Cas nuclease technology><Cell Body><Cells><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Co-Immunoprecipitations><Data><Development><Disease><Disease Outbreaks><Disorder><Dose><Epithelial Cells><Evolution><Exons><Ferrets><Flu vaccination><Genes><Genetic Alteration><Genetic Change><Genetic defect><Genetics-Mutagenesis><Genome><Genomics><Goals><Grippe><Hospital Admission><Hospitalization><Host Defense><Human><IFN><Immune Evasion><In Vitro><Influenza><Influenza A><Influenza A virus><Influenza Vaccines><Influenza Virus><Influenza Viruses Type A><Influenza immunization><Influenza vaccination><Influenzavirus A><Interferon Type I><Interferons><Invaded><KO mice><Knock-out Mice><Knockout Mice><Lung><Lung Respiratory System><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Membrane Protein Gene><Membrane Proteins><Membrane-Associated Proteins><Messenger RNA><Mice><Mice Mammals><Modern Man><Molecular><Molecular Interaction><Murine><Mus><Mutagenesis><Mutagenesis Molecular Biology><Mutate><Mutation><NIAID><NS Proteins><National Institute of Allergy and Infectious Disease><Nature><Non-structural Protein><Nonstructural Protein><Null Mouse><Orthomyxovirus Type A><Outbreaks><Pathogenesis><Pathway interactions><Pattern><Phenotype><Play><Polymerase><Population><Position><Positioning Attribute><Production><Prophylactic vaccination against influenza><Proteins><Proteomics><Research><Role><SCID Mice><Safety><Series><Severe Combined Immunodeficient Mice><Signal Pathway><Site><Strategic Planning><Surface><Surface Proteins><System><Testing><Type A Influenza><Vaccination><Vaccines><Viral><Viral Activity><Viral Function><Viral Gene Products><Viral Gene Proteins><Viral Genome><Viral Nonstructural Proteins><Viral Physiology><Viral Proteins><Virus><Virus Replication><Wild Type Mouse><adaptive immune response><aminoacid><anti-viral agents><anti-viral drugs><anti-viral therapy><anti-virals><base><cDNA Library><deep sequencing><density><developmental><flu immunisation><flu infection><flu vaccine><flu virus vaccine><genome mutation><immunogen><improved><in vivo><influenza infection><influenza virus vaccination><influenza virus vaccine><influenzavirus><knockout gene><mRNA><mouse model><murine model><mutant><novel><pandemic><pandemic disease><pathogen><pathogenic virus><pathway><programs><protein function><protein protein interaction><pulmonary><response><screening><social role><universal flu vaccine><universal influenza vaccine><universal vaccine><vaccination against influenza><vaccine against flu><vaccine against influenza><viral infectious disease treatment><viral multiplication><viral pathogen><viral replication><virus genome><virus host interaction><virus multiplication><virus protein><wildtype mouse>